|
2021 Conference Publication 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen Kaur, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Violet, John A., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2021). 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603). ASCO Genitourinary Cancers Symposium (GU ASCO), Online, 11-13 February 2021. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2021.39.6_suppl.6 |
|
2021 Journal Article Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): the NETPET score as a prognostic biomarkerChan, David L., Ulaner, Gary A., Pattison, David A., Wyld, David, Ladwa, Rahul, Kirchner, Julian, Li, Bob T, Lai, W Victoria, Pavlakis, Nick, Roach, Paul J and Bailey, Dale L (2021). Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): the NETPET score as a prognostic biomarker. Journal of Nuclear Medicine, 62 (9), 1278-1284. doi: 10.2967/jnumed.120.257659 |
|
2021 Journal Article Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 2, (477-482), 10.1007/s00259-020-04944-2)Roberts, Matthew J., Morton, Andrew, Donato, Peter, Kyle, Samuel, Pattison, David A., Thomas, Paul, Coughlin, Geoff, Esler, Rachel, Dunglison, Nigel, Gardiner, Robert A., Doi, Suhail A., Emmett, Louise and Yaxley, John (2021). Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 2, (477-482), 10.1007/s00259-020-04944-2). European Journal of Nuclear Medicine and Molecular Imaging, 48 (2), 655-656. doi: 10.1007/s00259-020-04983-9 |
|
2021 Journal Article Correction to: Prospective intra‑individual blinded comparison of [18F]PSMA‑1007 and [68 Ga]Ga‑PSMA‑11 PET/CT imaging in patients with confirmed prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 10.1007/s00259-021-05520-y)Pattison, David A., Debowski, Maciej, Gulhane, Brook, Arnfield, Evyn G., Pelecanos, Anita M., Garcia, Peter L., Latter, Melissa J., Lin, Charles Y., Roberts, Matthew J., Ramsay, Stuart C. and Thomas, Paul A. (2021). Correction to: Prospective intra‑individual blinded comparison of [18F]PSMA‑1007 and [68 Ga]Ga‑PSMA‑11 PET/CT imaging in patients with confirmed prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 10.1007/s00259-021-05520-y). European Journal of Nuclear Medicine and Molecular Imaging, 49 (2), 789-789. doi: 10.1007/s00259-021-05548-0 |
|
2021 Journal Article Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancerPattison, David A., Debowski, Maciej, Gulhane, Brook, Arnfield, Evyn G., Pelecanos, Anita M., Garcia, Peter L., Latter, Melissa J., Lin, Charles Y., Roberts, Matthew J., Ramsay, Stuart C. and Thomas, Paul A. (2021). Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 49 (2), 763-776. doi: 10.1007/s00259-021-05520-y |
|
2020 Journal Article Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case reportDhanani, Jayesh, Pattison, David A., Burge, Matthew, Williams, Julian, Riedel, Bernhard, Hicks, Rodney J. and Reade, Michael C. (2020). Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. Journal of Critical Care, 60, 319-322. doi: 10.1016/j.jcrc.2020.08.011 |
|
2020 Journal Article The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CTDudoignon, David, Pattison, David A., Legallois, Damien, Hicks, Rodney J. and Aide, Nicolas (2020). The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. Cancer Imaging, 20 (1) 68, 1-12. doi: 10.1186/s40644-020-00344-9 |
|
2020 Journal Article 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerRoberts, Matthew J., Morton, Andrew, Donato, Peter, Kyle, Samuel, Pattison, David A., Thomas, Paul, Coughlin, Geoff, Esler, Rachel, Dunglison, Nigel, Gardiner, Robert A., Doi, Suhail A., Emmett, Louise and Yaxley, John (2020). 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48 (2), 655-656. doi: 10.1007/s00259-020-04944-2 |
|
2020 Journal Article Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancerViolet, John, Sandhu, Shahneen, Iravani, Amir, Ferdinandus, Justin, Sue-Ping Thang, , Kong, Grace, Kumar, Aravind Ravi, Akhurst, Tim, Pattison, David, Beaulieu, Alexis, Mooi, Jennifer, Tran, Ben, Guo, Christina, Kalff, Victor, Murphy, Declan G., Jackson, Price, Eu, Peter, Scalzo, Mark, Williams, Scott G., Hicks, Rod J., Hofman, Michael S. and Tran, Ben (2020). Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine, 61 (6), 857-865. doi: 10.2967/jnumed.119.236414 |
|
2020 Journal Article Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate CancerViolet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S. P., Kong, G., Kumar, A. Ravi, Akhurst, T., Pattison, D. A., Beaulieu, A., Mooi, J., Guo, C., Kalff, V., Murphy, D. G., Jackson, P., Eu, P., Scalzo, M., Williams, S., Hicks, R. J. and Hofman, M. S. (2020). Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer. Journal of Urology, 203 (5). doi: 10.1097/JU.0000000000000779.01 |
|
2019 Conference Publication Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]Sandhu, Shahneen, Tothill, Richard, Scolyer, Richard, Guminski, Alexander, Becker, Juergen, Poulsen, Michael, Atkinson, Victoria, Neeson, Paul, Shackleton, Mark, Pattison, David, Williams, Narelle and Paton, Elizabeth (2019). Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, SA, Australia, 12–14 November 2019. Hoboken, NJ, United States: Wiley. |
|
2019 Conference Publication A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancerDebowski, M., Gulhane, B., Ramsay, S. C., Thomas, P. A., Garcia, P., Latter, M., Tapper, S. and Pattison, D. A. (2019). A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. Australian and New Zealand Society of Nuclear Medicine (ANZSNM) 49th ASM, Adelaide, SA, Australia, 26–28 April 2019. Hoboken, NJ, United States: Wiley. |
|
2018 Conference Publication Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD)Scott, Ashleigh P., Tey, Siok-Keen, Thomas, Paul, Pattison, David and Kennedy, Glen A. (2018). Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD). 60th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-114114 |
|
2018 Journal Article 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapyHicks, Rodney J., Jackson, Price, Kong, Grace, Ware, Robert E., Hofman, Michael S., Pattison, David A., Akhurst, Timothy A., Drummond, Elizabeth, Roselt, Peter, Callahan, Jason, Price, Roger, Jeffery, Charmaine M., Hong, Emily, Noonan, Wayne, Herschtal, Alan, Hicks, Lauren J., Hedt, Amos, Harris, Matthew, Paterson, Brett M. and Donnelly, Paul S. (2018). 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. Journal of Nuclear Medicine, 60 (6), 777-785. doi: 10.2967/jnumed.118.217745 |
|
2018 Conference Publication (18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKERobinson, B., Pattison, D. and Lee, K. (2018). (18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKE. HOBOKEN: WILEY. |
|
2018 Journal Article Lymphangitic carcinomatosis from prostate cancer identified with gallium-68 prostate-specific membrane antigen positron emission tomography imagingTang, Victor, Campbell, Patrina and Pattison, David A. (2018). Lymphangitic carcinomatosis from prostate cancer identified with gallium-68 prostate-specific membrane antigen positron emission tomography imaging. Urology, 114, e1-e2. doi: 10.1016/j.urology.2017.12.010 |
|
2018 Journal Article Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and68Ga-DOTATATE PET/CTBongetti, Elisa, Lee, Melissa H., Pattison, David A., Hicks, Rodney J., Norris, Richard, Sachithanandan, Nirupa and MacIsaac, Richard J. (2018). Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and68Ga-DOTATATE PET/CT. Clinical Case Reports, 6 (4), 719-722. doi: 10.1002/ccr3.1448 |
|
2018 Journal Article Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumorsLadwa, Rahul, Wen Hong, Hooi, Wyld, David, Pattison, David A. and Burge, Matthew (2018). Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumors. Clinical Nuclear Medicine, 43 (3), 186-187. doi: 10.1097/RLU.0000000000001970 |
|
2018 Conference Publication Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumorsLadwa, R., Pattison, D., Smith, J., Goodman, S., Burg, M., Rose, S., Dowson, N. and Wyld, D. (2018). Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Conference Publication Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECTGoodman, Steven , Patford, Shaun , Ladwa, Rahul , Smith, Jye , Wyld, David and Pattison, David A. (2018). Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECT. 12th Congress of the World Federation of Nuclear Medicine and Biology., Melbourne Australia, 20-24 April 2018. |
